Literature DB >> 16981896

Distribution of the FcgammaRIIIa 176 F/V polymorphism amongst healthy Chinese, Malays and Asian Indians in Singapore.

K T Chong1, W F Ho, S H Koo, Peter Thompson, Edmund J D Lee.   

Abstract

AIMS: To determine and compare the distribution of the FcgammaRIIIa 176 F/V polymorphism across three ethnically distinct populations (Chinese, Asian Indians and Malays) in Singapore.
METHODS: The FcgammaRIIIa 176 F/V polymorphism was genotyped by direct sequencing from genomic DNA samples obtained from normal healthy Chinese, Asian Indians and Malays (n = 192 from each population).
RESULTS: The allelic frequencies of the high binding affinity FcgammaRIIIa 176 V allele for Chinese, Asian Indians and Malays were 35%, 33% and 46%, respectively (F allele frequencies were 65%, 67% and 54%, respectively). Genotype distributions were found to conform to the Hardy-Weinberg law (P > 0.05) in each group. chi(2) comparisons revealed significant differences in the genotype distributions of the FcgammaRIIIa 176 V/F polymorphism of Malays from the other two populations (Chinese and Asian Indians). However, no significant difference in the genotype distributions of the FcgammaRIIIa 176 V/F polymorphism was observed between Chinese and Asian Indian populations.
CONCLUSIONS: The genotype distributions of the FcgammaRIIIa 176 V/F polymorphism in healthy Malays are significantly different from both Chinese and Indians. These observations provide the fundamentals on which future disease associations may be built and also present important implications for the design of therapeutic regimens amongst various ethnic groups.

Entities:  

Mesh:

Year:  2006        PMID: 16981896      PMCID: PMC2000731          DOI: 10.1111/j.1365-2125.2006.02771.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  28 in total

1.  Variant genotypes of the low-affinity Fcgamma receptors in two control populations and a review of low-affinity Fcgamma receptor polymorphisms in control and disease populations.

Authors:  T Lehrnbecher; C B Foster; S Zhu; S F Leitman; L R Goldin; K Huppi; S J Chanock
Journal:  Blood       Date:  1999-12-15       Impact factor: 22.113

2.  Ethnic variation of Fc gamma receptor polymorphism in Sami and Norwegian populations.

Authors:  Oivind Torkildsen; Egil Utsi; Svein Ivar Mellgren; Hanne F Harbo; Christian A Vedeler; Kjell-Morten Myhr
Journal:  Immunology       Date:  2005-07       Impact factor: 7.397

Review 3.  IgG receptor polymorphisms: risk factors for disease.

Authors:  W van der Pol; J G van de Winkel
Journal:  Immunogenetics       Date:  1998-08       Impact factor: 2.846

4.  Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia.

Authors:  Steven P Treon; Mark Hansen; Andrew R Branagan; Sigitas Verselis; Christos Emmanouilides; Eva Kimby; Stanley R Frankel; Nikolaos Touroutoglou; Barry Turnbull; Kenneth C Anderson; David G Maloney; Edward A Fox
Journal:  J Clin Oncol       Date:  2005-01-20       Impact factor: 44.544

5.  Severity of Guillain-Barré syndrome is associated with Fc gamma Receptor III polymorphisms.

Authors:  Nina M van Sorge; W-Ludo van der Pol; Marc D Jansen; Karin P W Geleijns; Sandra Kalmijn; Richard A C Hughes; Jeremy H Rees; Jane Pritchard; Christian A Vedeler; Kjell-Morten Myhr; Chris Shaw; Ivo N van Schaik; John H J Wokke; Pieter A van Doorn; Bart C Jacobs; Jan G J van de Winkel; Leonard H van den Berg
Journal:  J Neuroimmunol       Date:  2005-05       Impact factor: 3.478

Review 6.  Receptors for immunoglobulin G. Molecular diversity and implications for disease.

Authors:  R P Kimberly; J E Salmon; J C Edberg
Journal:  Arthritis Rheum       Date:  1995-03

7.  Ethnic variation in frequency of an allelic polymorphism of human Fc gamma RIIA determined with allele specific oligonucleotide probes.

Authors:  J M Osborne; G W Chacko; J T Brandt; C L Anderson
Journal:  J Immunol Methods       Date:  1994-08-01       Impact factor: 2.303

8.  Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype.

Authors:  Wen-Kai Weng; Debra Czerwinski; John Timmerman; Frank J Hsu; Ronald Levy
Journal:  J Clin Oncol       Date:  2004-10-13       Impact factor: 44.544

9.  The Fc gammaRIIIA-158F allele is a risk factor for systemic lupus erythematosus.

Authors:  H R Koene; M Kleijer; A J Swaak; K E Sullivan; M Bijl; M A Petri; C G Kallenberg; D Roos; A E von dem Borne; M de Haas
Journal:  Arthritis Rheum       Date:  1998-10

10.  Correlation of platelet Fc gammaRIIA polymorphism in refractory idiopathic (immune) thrombocytopenic purpura.

Authors:  Y Williams; S Lynch; S McCann; O Smith; C Feighery; A Whelan
Journal:  Br J Haematol       Date:  1998-06       Impact factor: 6.998

View more
  4 in total

1.  Stimulation of natural killer cells with rhCD137 ligand enhances tumor-targeting antibody efficacy in gastric cancer.

Authors:  Toshihiro Misumi; Kazuaki Tanabe; Nobuaki Fujikuni; Hideki Ohdan
Journal:  PLoS One       Date:  2018-10-15       Impact factor: 3.240

2.  FcγRIIIa receptor polymorphism influences NK cell mediated ADCC activity against HIV.

Authors:  Sneha Pramod Talathi; Nawaj Najir Shaikh; Sudhanshu Shekhar Pandey; Vandana Ashish Saxena; Megha Sunil Mamulwar; Madhuri Rajeev Thakar
Journal:  BMC Infect Dis       Date:  2019-12-16       Impact factor: 3.090

3.  Novel TLR 7/8 agonists for improving NK cell mediated antibody-dependent cellular cytotoxicity (ADCC).

Authors:  Vidhi Khanna; Hyunjoon Kim; Wenqiu Zhang; Peter Larson; Manan Shah; Thomas S Griffith; David Ferguson; Jayanth Panyam
Journal:  Sci Rep       Date:  2021-02-08       Impact factor: 4.379

4.  A comprehensive overview of FCGR3A gene variability by full-length gene sequencing including the identification of V158F polymorphism.

Authors:  Niken M Mahaweni; Timo I Olieslagers; Ivan Olivares Rivas; Stefan J J Molenbroeck; Mathijs Groeneweg; Gerard M J Bos; Marcel G J Tilanus; Christina E M Voorter; Lotte Wieten
Journal:  Sci Rep       Date:  2018-10-29       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.